- Home
- COYA vs TLSA Comparison
COYA vs TLSA Comparison
Compare COYA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- TLSA
- Stock Information
- Founded
- COYA 2020
- TLSA 2013
- Country
- COYA United States
- TLSA United Kingdom
- Employees
- COYA N/A
- TLSA N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- TLSA Health Care
- Exchange
- COYA Nasdaq
- TLSA Nasdaq
- Market Cap
- COYA 93.9M
- TLSA 87.8M
- IPO Year
- COYA 2022
- TLSA 2000
- Fundamental
- Price
- COYA $5.38
- TLSA $0.74
- Analyst Decision
- COYA Strong Buy
- TLSA
- Analyst Count
- COYA 4
- TLSA 0
- Target Price
- COYA $16.25
- TLSA N/A
- AVG Volume (30 Days)
- COYA 62.0K
- TLSA 442.0K
- Earning Date
- COYA 11-06-2024
- TLSA 01-28-2025
- Dividend Yield
- COYA N/A
- TLSA N/A
- EPS Growth
- COYA N/A
- TLSA N/A
- EPS
- COYA N/A
- TLSA N/A
- Revenue
- COYA $9,554,315.00
- TLSA N/A
- Revenue This Year
- COYA N/A
- TLSA N/A
- Revenue Next Year
- COYA $87.80
- TLSA N/A
- P/E Ratio
- COYA N/A
- TLSA N/A
- Revenue Growth
- COYA N/A
- TLSA N/A
- 52 Week Low
- COYA $4.75
- TLSA $0.41
- 52 Week High
- COYA $10.69
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- COYA 38.98
- TLSA 44.91
- Support Level
- COYA $5.52
- TLSA $0.68
- Resistance Level
- COYA $6.14
- TLSA $0.80
- Average True Range (ATR)
- COYA 0.44
- TLSA 0.08
- MACD
- COYA -0.01
- TLSA 0.01
- Stochastic Oscillator
- COYA 5.13
- TLSA 34.34
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.